Follow The Filings

GMED Globus Medical Inc.

Health Care, filed as GLOBUS MED INC (CL A), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q3

  • 1 Owner
  • Max 0.1%
  • $4.3M
  • 1 add

In 2026 Q3 Ruane, Cunniff & Goldfarb added to Globus Medical.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Ruane, Cunniff & Goldfarb). Not free-float ownership.

  1. Ruane, Cunniff & Goldfarb Add 0.07%

Who owns GMED

Sorted by value, long equity only, as of 2026 Q3.

History
Ruane, Cunniff & Goldfarb 0.07%, was 0.01% Add +854.9% 57,371 $4.3M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by GMED's executives, directors and 10% owners in the last 12 months, from their Form 4s

All GMED insider trades
  • None no insider bought on the open market
  • $9.6M sold by 3 insiders outside a trading plan
  • $6.5M sold by 4 insiders under 10b5-1 plans
  1. James R. Tobin Director
    Sale
    $3.1M 41,666 shares at $75.16 100% of stake
    Traded Nov 10 Filed Nov 12
  2. Ann D. Rhoads Director
    Planned sale
    $425K 5,000 shares at $85.00 12% of stake
    Traded Nov 4 Filed Nov 5
  3. James R. Tobin Director
    Sale
    $2.2M 30,000 shares at $74.58 100% of stake
    Traded Sep 15 Filed Sep 16
  4. Stephen T. Zarrilli Director
    Sale
    $2.2M 25,000 shares at $87.04 100% of stake
    Traded Aug 18 Filed Aug 19
  5. David D. Davidar Director
    Sale
    $2M 25,000 shares at $80.76 4.7% of stake
    Traded Jun 5 Filed Jun 9
  6. Kelly Huller EVP, GC, Corporate Secretary
    Planned sale
    $1.9M 20,000 shares at $94.50 100% of stake
    Traded Feb 25 Filed Feb 27
  7. Kelly Huller EVP, GC, Corporate Secretary
    Planned sale
    $877K 10,000 shares at $87.67 100% of stake
    Traded Feb 12 Filed Feb 17
  8. Kyle Kline CFO
    Planned sale
    $363K 3,594 shares at $101.10 100% of stake
    Traded Jan 8 Filed Jan 12
  9. Leslie V. Norwalk Director
    Planned sale
    $202K 2,000 shares at $101.10 16% of stake
    Traded Jan 8 Filed Jan 12
  10. Leslie V. Norwalk Director
    Planned sale
    $355K 4,000 shares at $88.85 24% of stake
    Traded Dec 12, 2025 Filed Dec 16, 2025
  11. Kyle Kline CFO
    Planned sale
    $1.7M 18,542 shares at $90.00 100% of stake
    Traded Dec 1, 2025 Filed Dec 3, 2025
  12. Kelly Huller SVP, GC, Corporate Secretary
    Planned sale
    $675K 7,500 shares at $90.00 100% of stake
    Traded Nov 25, 2025 Filed Nov 28, 2025
  13. David D. Davidar Director
    Sale
    $2.2M 25,000 shares at $86.00 4.6% of stake
    Traded Nov 12, 2025 Filed Nov 13, 2025
  14. Stephen T. Zarrilli Director
    Sale
    $2.1M 25,000 shares at $84.29 100% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
  15. Ann D. Rhoads Director
    Planned sale
    $818K 10,000 shares at $81.80 39% of stake
    Traded Nov 7–10 Filed Nov 10, 2025

Also filed in the last 12 months, not counted as buying or selling: 17 option exercises and 1 gift.

Congress

3 members of Congress traded GMED in the last three years: 4 buys and 3 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Sep 3 filed Oct 12
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $15K–$50K Aug 19 filed Sep 10
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  4. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Jul 10, 2025 filed Aug 13, 2025
  5. Lisa C. McClain R-MI-9Spouse Partial sale $1K–$15K Jun 24, 2025 filed Aug 13, 2025
  6. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Jun 17, 2025 filed Aug 13, 2025

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
10-Q
8-K 2.02,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.02,5.07,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
DEF 14A
DEFA14A
SCHEDULE 13G/A —
8-K 5.02,7.01,9.01
8-K 2.02,9.01
10-K

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.57B $2.52B $2.94B
Gross profit * $1.02B $1.48B $1.98B
Gross margin * 65.1% 58.9% 67.4%
Net income $122.87M $102.98M $537.87M
Net margin * 7.8% 4.1% 18.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.92B $2.18B $2.13B
Total non-current assets * $3.17B $3.07B $3.18B
Total assets $5.09B $5.25B $5.3B
Total current liabilities $392.35M $855.91M $498.5M
Total non-current liabilities * $695.78M $218.5M $231.01M
Total equity $4B $4.18B $4.57B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $243.5M $520.64M $753.45M
Cash from investing $302.97M -$176.05M -$355.01M
Cash from financing -$231.82M -$27.7M -$679.16M
Net change in cash $316.83M $317.15M -$258.28M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf